Article: Rizatriptan

Rizatriptan
Systematic (IUPAC) name
N,N-dimethyl-2- [5-(1,2,4-triazol-1-ylmethyl)- 1H-indol-3-yl]ethanamine
Identifiers
CAS number	145202-66-0
ATC code	N02CC04
PubChem	5078
DrugBank	APRD00008
Chemical data
Formula	C15H19N5
Mol. weight	269.345 g/mol
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	MAO
Half life	2-3 hours
Excretion	82% urine; 12% feces
Therapeutic considerations
Pregnancy cat.	C
Legal status
Routes	tablet

Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the Food and Drug Administration (FDA) on June 29, 1998. It represents a second-generation triptan.

Rizatriptan is available only by prescription in the United States and Canada.

This medication is used to treat acute migraine attacks. This drug does not prevent future migraine attacks.